Three-Year Results of Medtronic's Evolut TAVR Compared to Surgery in Low Risk Patients Presented at ACC

The 3-year comparative data for Medtronic's CoreValve/Evolut TAVR vs. SAVR for low risk patients that were presented at today's late-breaking clinical trials session were much needed and the results showed that this device compared favorably with surgery and, in some respects, was superior.
Source: News from Angioplasty.Org - Category: Cardiology Source Type: news